BGPartner announces the promotion of Fabiola Anthamatten (pictured left) to managing associate and Thomas Gysin (pictured right) to senior associate. Both have been an integral part of the BGPartner team for several years.
Tags :Fabiola Anthamatten
Numab Therapeutics, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, successfully closes CHF 100 million (approximately USD 110 million) in Series C financing Round. The financing was co-led by new investors
